PIM1

PIM1 is a constitutively active serine/threonine kinase that regulates cell survival, proliferation, cell-cycle progression, and apoptosis through phosphorylation of multiple downstream substrates involved in oncogenic signaling networks^[1]. Mechanistically, PIM1 functions downstream of cytokine-responsive pathways, particularly JAK/STAT signaling, and cooperates with pathways including PI3K/AKT/mTOR, MYC, and NF-κB to promote cellular growth, metabolic adaptation, and resistance to stress signals^[2][3]. In disease contexts, PIM1 is frequently overexpressed in hematologic malignancies, prostate cancer, and several solid tumors, where elevated activity is associated with tumor progression, survival advantages, and therapeutic resistance^[3][4]. Experimental studies further demonstrate that PIM1 contributes to tumorigenicity, cellular migration, invasion, and maintenance of aggressive cancer phenotypes, supporting its value as a mechanistic target in cancer biology research^[5][6]. Compared with the related isoforms PIM2 and PIM3, PIM1 shares a highly conserved catalytic domain and overlapping substrate specificity, yet displays distinct expression patterns and context-dependent biological functions that influence disease phenotypes and therapeutic responses^[7][8]. For experimental applications, the unique ATP-binding pocket of PIM kinases has enabled development of selective and pan-PIM inhibitors, including SGI-1776, AZD1208, CX-6258, and TP-3654, which are widely used to investigate PIM-dependent signaling, proliferation, apoptosis, and drug-resistance mechanisms in preclinical models^[3][7][9].